Sci Signal:抗癌药物或可用于治疗肌肉变性疾病

2013-05-06 T.Shen 生物谷

2012年10月17日目前治疗肌肉损伤的药物很少,肌萎缩和家族性遗传病可以引发肌肉变性,比如迪谢纳肌营养不良症。近日,一项研究发现或许帮助医生们治疗这种肌肉疾病,相关研究由渥太华大学医学院等处的研究者进行,研究成果刊登于10月16日的国际杂志Science Signaling上。 研究者Korneluk教授表示,我们都知道,目前很多制药公司都在积极推进抗癌药物的研发和临床试验,这些抗癌药物都以I

2012年10月17日目前治疗肌肉损伤的药物很少,肌萎缩和家族性遗传病可以引发肌肉变性,比如迪谢纳肌营养不良症。近日,一项研究发现或许帮助医生们治疗这种肌肉疾病,相关研究由渥太华大学医学院等处的研究者进行,研究成果刊登于10月16日的国际杂志Science Signaling上。

研究者Korneluk教授表示,我们都知道,目前很多制药公司都在积极推进抗癌药物的研发和临床试验,这些抗癌药物都以IAP基因为靶点,IAP基因所编码的蛋白质是和肿瘤生长相关的一个蛋白质家族。如今研究者将IAP基因的角色同肌肉疾病联系了起来,研究者发现以IAP为靶点的药物可以促进癌症细胞死亡,于此同时可以诱导和修复肌肉组织。研究者也通过激活特殊的信号交流路径来鉴别出了这一过程发生的分子机制。这项路径通过促进肌肉细胞融合形成新的肌肉纤维来修复肌肉组织,从而达到控制肌肉生长以及修复的作用。

演技足额和希望在未来通过进行相应的临床试验来验证其结果,研究小组同时也发现了一些肌肉增强效应的药物可以重复作为一种生长因子在机体进行作用,称为TWEAK。当其水平较低时,相同的信号路径就会被激活,从而促进损伤肌肉组织的修复。

这项研究由加拿大卫生研究院等机构提供支持。

肌肉相关的拓展阅读:

TWEAK and cIAP1 Regulate Myoblast Fusion Through the Noncanonical NF-B Signaling Pathway

The fusion of mononucleated muscle progenitor cells (myoblasts) into multinucleated muscle fibers is a critical aspect of muscle development and regeneration. We identified the noncanonical nuclear factor B (NF-B) pathway as a signaling axis that drives the recruitment of myoblasts into new muscle fibers. Loss of cellular inhibitor of apoptosis 1 (cIAP1) protein led to constitutive activation of the noncanonical NF-B pathway and an increase in the number of nuclei per myotube. Knockdown of essential mediators of NF-B signaling, such as p100, RelB, inhibitor of B kinase α, and NF-B–inducing kinase, attenuated myoblast fusion in wild-type myoblasts. In contrast, the extent of myoblast fusion was increased when the activity of the noncanonical NF-B pathway was enhanced by increasing the abundance of p52 and RelB or decreasing the abundance of tumor necrosis factor (TNF) receptor–associated factor 3, an inhibitor of this pathway. Low concentrations of the cytokine TNF-like weak inducer of apoptosis (TWEAK), which preferentially activates the noncanonical NF-B pathway, also increased myoblast fusion, without causing atrophy or impairing myogenesis. These results identify roles for TWEAK, cIAP1, and noncanonical NF-B signaling in the regulation of myoblast fusion and highlight a role for cytokine signaling during adult skeletal myogenesis.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1793949, encodeId=21cd1e939491d, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Dec 08 18:43:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036114, encodeId=83c6203611438, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Mon Jun 10 04:43:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308189, encodeId=b030130818927, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314583, encodeId=d4b21314583e0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463471, encodeId=ff2314634e12b, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-12-08 yaanren
  2. [GetPortalCommentsPageByObjectIdResponse(id=1793949, encodeId=21cd1e939491d, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Dec 08 18:43:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036114, encodeId=83c6203611438, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Mon Jun 10 04:43:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308189, encodeId=b030130818927, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314583, encodeId=d4b21314583e0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463471, encodeId=ff2314634e12b, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-06-10 楚秀娟
  3. [GetPortalCommentsPageByObjectIdResponse(id=1793949, encodeId=21cd1e939491d, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Dec 08 18:43:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036114, encodeId=83c6203611438, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Mon Jun 10 04:43:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308189, encodeId=b030130818927, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314583, encodeId=d4b21314583e0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463471, encodeId=ff2314634e12b, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1793949, encodeId=21cd1e939491d, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Dec 08 18:43:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036114, encodeId=83c6203611438, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Mon Jun 10 04:43:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308189, encodeId=b030130818927, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314583, encodeId=d4b21314583e0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463471, encodeId=ff2314634e12b, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-05-08 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1793949, encodeId=21cd1e939491d, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Dec 08 18:43:00 CST 2013, time=2013-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036114, encodeId=83c6203611438, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Mon Jun 10 04:43:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308189, encodeId=b030130818927, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314583, encodeId=d4b21314583e0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463471, encodeId=ff2314634e12b, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-05-08 huangdf

相关资讯

Open Biol:抗氧化剂对癌症患者有害

  近日,曾因发现DNA双螺旋结构而分享诺贝尔医学与生理学奖的Jim Watson教授公布了一个有关活性氧分子(ROS)的假说,认为肿瘤细胞内的抗氧化物水平与肿瘤细胞耐药有关。换句话说,含有抗氧化剂(包括β-胡萝卜素、维生素A、C和E以及硒等)的营养品对肿瘤患者有害。(Open Biol.2013年1月8日在线版)   Watson指出,用来直接杀死肿瘤细胞的绝大多数药物或物

H7N9:禽流感病毒可抗癌细胞

  弗吉尼亚理工大学弗吉尼亚马里区,兽医学院的病毒学副教授Elankumaran Subbiah博士,主攻鸡新城鸡疫病毒(Newcastle disease virus)的抗癌特性,他最近的一项研究证实了鸡新城鸡疫病毒在人类前列腺癌中的治疗作用。相关研究结果发表在4月8日的《癌症》杂志上。   Elankumaran Subbiah博士与兽医学院的主任Si

Cell:抗衰老基因可抗癌

  近期一项研究进一步探索了抗衰老基因的抗癌功效。据密歇根大学与哈佛医学院联合进行的一项研究显示,实验小鼠体内如果缺少了SIRT6蛋白,其体内肿瘤的数量、体积和严重程度就会增加。此外,该研究还表明,SIRT6缺失还会促进人类结肠癌与胰腺癌肿瘤的生长。   联合研究员、密歇根大学医学院教授David Lombard称:“弄清楚可抑制肿瘤发展的基因图谱具有重要意义。我们的研究表明SIRT6或在阻

PNAS:癌症复发的关键酶:ADAR1

  慢性粒细胞性白血病CML是一种血液和骨髓癌,其患病率正在逐年增加。日前,加州大学圣迭戈分校医学院的研究人员发现,在促进干细胞恶意增殖和CML发展的重编程过程中存在着一种关键的酶。这一发现提前发表在十二月二十四日美国国家科学院院刊PNAS杂志的网站上。   美国目前有七万人患有CML,预计到2050年这一数字将稳定增长到约181000人。CML是BCR-ABL基因突变引起的,但科学家尚还不清楚

JCEM:Beclin1具有独立于自噬的抗癌效应

泛素–蛋白酶体系统和自噬是细胞内蛋白质降解的两条主要的途径。新兴的证据显示蛋白酶体抑制剂通过阻断泛素–蛋白酶体系统激活自噬。为了确定自噬必需基因Beclin1在蛋白酶体抑制剂介导的甲状腺癌细胞细胞毒性中的作用,来自中国医科大学第一附属医院老年科的张海燕教授及其团队进行了一项研究,该研究发现甲状腺癌细胞暴露于蛋白酶体抑制剂之上时,Beclin1具有独立于自噬的抗癌作用。该研究结果发表在2013年2月

Genet in Med:抗癌药物或可助力庞贝氏症患者的治疗

通过将抗癌药物与当前疗法的药物混合可以使得患有严重庞贝氏症的婴儿疾病得到明显的缓解甚至治愈,庞贝氏症是一种罕见的致死性的遗传病,其主要表现为婴儿机体的某种酶类缺少或者水平极低,导致婴儿死亡。此前研究中,来自杜克大学的研究者使用酶替代疗法(ERT)来治疗庞贝氏症,这项新的研究中,研究者对此前的疗法进行了改进和补充,相关研究成果刊登在了10月11日的国际杂志Genetics in Medicine上。